These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34916339)

  • 41. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
    Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
    Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
    Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
    Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
    Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
    J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
    [No Abstract]   [Full Text] [Related]  

  • 44. [Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis].
    Fujishima M; Fujishima N; Kitadate A; Guo Y; Watanabe A; Ubukawa K; Nara M; Yoshioka T; Kameoka Y; Takahashi N
    Rinsho Ketsueki; 2017; 58(7):743-748. PubMed ID: 28781268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
    Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
    Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
    Verstovsek S; Kantarjian HM; Estrov Z; Cortes JE; Thomas DA; Kadia T; Pierce S; Jabbour E; Borthakur G; Rumi E; Pungolino E; Morra E; Caramazza D; Cazzola M; Passamonti F
    Blood; 2012 Aug; 120(6):1202-9. PubMed ID: 22718840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
    Chen X; Williams WV; Sandor V; Yeleswaram S
    J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
    Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
    Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis.
    Komatsu N; Kirito K; Shimoda K; Ishikawa T; Ohishi K; Ohyashiki K; Takahashi N; Okada H; Amagasaki T; Yonezu T; Akashi K
    Int J Hematol; 2017 Mar; 105(3):309-317. PubMed ID: 27832516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors.
    Randhawa J; Ostojic A; Vrhovac R; Atallah E; Verstovsek S
    J Hematol Oncol; 2012 Aug; 5():43. PubMed ID: 22852872
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ruxolitinib.
    Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
    Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
    Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
    Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S
    N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
    Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
    Al-Ali HK; Griesshammer M; le Coutre P; Waller CF; Liberati AM; Schafhausen P; Tavares R; Giraldo P; Foltz L; Raanani P; Gupta V; Tannir B; Ronco JP; Ghosh J; Martino B; Vannucchi AM
    Haematologica; 2016 Sep; 101(9):1065-73. PubMed ID: 27247324
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
    Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
    Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.